https://www.fool.com/investing/2019/07/12/heres-why-beigene-lost-116-in-the-first-half-of-20.aspx
China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.
beigenelostfirst
https://www.pharmaceutical-technology.com/data-insights/bgb-15025-beigene-gastric-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-217874&utm_campaign=recommended-articles-pi
BGB-15025 is under clinical development by BeiGene and currently in Phase I for Gastric Cancer.
gastric cancerbgbbeigenelikelihoodapproval
https://www.ainvest.com/news/beigene-patent-victory-turning-point-brukinsa-market-dominance-2504/
BeiGene's Patent Victory: A Turning Point for BRUKINSA and Market Dominance
turning pointbeigenepatentvictorybrukinsa
https://www.pharmaceutical-technology.com/data-insights/bgb-15025-beigene-non-small-cell-lung-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-217875&utm_campaign=recommended-articles-pi
BGB-15025 is under clinical development by BeiGene and currently in Phase I for Non-Small Cell Lung Cancer.
small celllung cancerbgbbeigenenon
https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-relapsed-multiple-myeloma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-228846&utm_campaign=recommended-articles-pi
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Relapsed Multiple Myeloma.
multiple myelomasonrotoclaxbeigenerelapsedlikelihood
https://www.benzinga.com/general/biotech/23/07/33185448/why-are-beigene-shares-trading-lower-today
BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to
shares tradingbeigenelowertodaynovartis
https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-merkel-cell-carcinoma-likelihood-of-approval/
BGB-30813 is under clinical development by BeiGene and currently in Phase I for Merkel Cell Carcinoma.
merkel cell carcinomabgbbeigenelikelihood
https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-metastatic-melanoma-likelihood-of-approval/
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Metastatic Melanoma.
metastatic melanomabgbbeigenelikelihoodapproval
https://www.globenewswire.com/news-release/2018/05/17/1508005/0/en/BeiGene-Initiates-Phase-3-Trial-of-Pamiparib-as-Maintenance-Therapy-in-Chinese-Patients-with-Ovarian-Cancer.html
BEIJING, China and CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused...
beigeneinitiatesphasetrialpamiparib
https://www.pharmaceutical-technology.com/data-insights/cdk4-inhibitor-beigene-breast-cancer-likelihood-of-approval/
CDK4 Inhibitor is under clinical development by BeiGene and currently in Phase I for Breast Cancer.
breast cancerinhibitorbeigenelikelihoodapproval
https://www.healthrelations.de/allgemein/martin-voelkl-general-manager-beigene-germany/
Sep 8, 2025 - Wie BeOne Medicines den Namenwechsel nutzt, um interne Vernetzung und externe Sichtbarkeit zu stärken – und wo die Reise hingeht.
vonbeigenezubeonemehr
https://www.businesswire.com/news/home/20240508878785/en/BeiGene-Reports-First-Quarter-2024-Financial-Results-and-Business-Updates
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced results from the first quarter 2024 and business highlight...
first quarterfinancial resultsbusiness updatesbeigenereports
https://www.clinicaltrialsarena.com/news/immunitybio-beigene-trial-nsclc/
ImmunityBio has partnered with BeiGene for conducting the trial combining tislelizumab and Anktiva to treat advanced or metastatic NSCLC.
beigenepartnertrialnsclctreatment
https://www.pharmaceutical-technology.com/data-insights/bgb-43395-beigene-non-small-cell-lung-cancer-likelihood-of-approval/
BGB-43395 is under clinical development by BeiGene and currently in Phase I for Non-Small Cell Lung Cancer.
small celllung cancerbgbbeigenenon
https://www.businesswire.com/news/home/20220907006312/en/BeiGene-to-Present-at-the-Morgan-Stanley-20th-Annual-Global-Healthcare-Conference
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology...
morgan stanleybeigenepresentannualglobal
https://www.ig.com/za/shares/markets-shares/beigene-ltd
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients... [ZA]
share pricetradebeigeneltdshares